オーファンドラッグの世界市場レポート 2024

オーファンドラッグの市場規模は、今後数年間で急激に成長すると予想されています。 2028年には23.4%の年間複合成長率（CAGR）で4,816億9,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、市場アクセス政策の発展、価値ベースのヘルスケアへの取り組み、市場の世界の拡大、患者中心の医薬品開発、希少がんの標的化への注力に関連している可能性があります。予測期間における注目すべき動向には、標的特定の増加、加速された規制経路の実施、遺伝子治療の進歩、調査における協力の拡大、精密医療アプローチの採用が含まれます。

オーファンドラッグ市場の成長は、希少疾患の蔓延によって大きく推進されています。人口のごく一部が罹患している希少疾患は、多くの場合コールドチェーン（すべての国で普遍的に利用できるわけではない、温度管理されたサプライチェーン）を必要とする治療を必要とします。世界的に希少疾患の有病率が増加しており、2022年1月現在、米国で毎年約5万4,000人の新たな中咽頭がんまたは口腔がんの症例が報告されていることがその例です。これらの癌による死亡者数は11,230人であり、希少疾病の罹患率が若年層でも増加していることがオーファンドラッグ市場の原動力となっています。

血液学の分野でのオーファンドラッグの利用の増加により、オーファンドラッグ市場が前進する態勢が整っています。血液学は、血液関連疾患に焦点を当てた医学であり、希少血液疾患や希少血液疾患に対する治療ソリューションを提供することでオーファンドラッグの恩恵を受けています。これらの薬剤は特定の遺伝子変異と細胞プロセスを標的とし、輸血の必要性を軽減し、疾患の合併症を最小限に抑え、患者の生活の質を向上させます。 2021年 6月の時点で、オーストラリアでは110,000人以上が血液疾患に苦しんでおり、2035年までにその数は275,000人を超えると予測されています。したがって、血液学におけるオーファンドラッグの適用の増加は、市場の成長の主要な推進力になると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のオーファンドラッグ市場、治療分野別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 腫瘍学
• 血液
• 中枢神経系
• 内分泌
• 心臓血管
• 呼吸器系
• 免疫調節性
• 世界のオーファンドラッグ市場、疾患タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 腫瘍学
• 血液学
• 神経内科
• 心臓血管
• 他の種類の病気
• 世界のオーファンドラッグ市場、医薬品タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 生物学的
• 非生物学的
• 世界のオーファンドラッグ市場、流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンライン販売

第7章 地域および国の分析

• 世界のオーファンドラッグ市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のオーファンドラッグ市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オーファンドラッグ市場の競合情勢
• オーファンドラッグ市場の企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson Services Inc.
  • F Hoffmann-La Roche Ltd.
  • Farbenfabriken Bayer AG
  • Novartis AG

第31章 その他の大手および革新的な企業

• Sanofi SA
• Bristol-Myers Squibb Co.
• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Applied Molecular Genetics Inc.
• Novo Nordisk A/S
• Merck &Co. KG
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• CSL Limited
• Biogen Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Orphan drugs are medications specifically formulated to address uncommon medical conditions. These drugs are designed to meet public health needs that are often neglected by the pharmaceutical industry due to financial constraints. The term "orphan" in this context refers to medications that may have been developed for a common condition but are also effective in treating a less prevalent medical issue.

Orphan drugs come in two main types biological and non-biological. They are employed in various therapeutic areas, including oncology, hematology, neurology, cardiovascular, respiratory, and immunomodulatory applications. Hematology specifically focuses on the study of blood and blood-related disorders. The distribution of these drugs is carried out through hospital pharmacies, retail pharmacies, and online sales.

The orphan drugs market research report is one of a series of new reports from The Business Research Company that provides orphan drugs market statistics, including orphan drugs industry global market size, regional shares, competitors with an orphan drugs market share, detailed orphan drugs market segments, market trends and opportunities, and any further data you may need to thrive in the orphan drugs industry. This orphan drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The orphan drugs market size has grown rapidly in recent years. It will grow from $188.45 billion in 2023 to $208.04 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historical period can be credited to factors such as the Orphan Drug Act of 1983, increasing attention to rare diseases, drug repurposing, advancements in genetic understanding, and initiatives for research funding.

The orphan drugs market size is expected to see exponential growth in the next few years. It will grow to $481.69 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The growth anticipated in the forecast period can be linked to developments in market access policies, initiatives for value-based healthcare, global expansion of the market, patient-centric drug development, and a focus on targeting rare cancers. Notable trends in the forecast period encompass the rise in target identification, the implementation of accelerated regulatory pathways, progress in gene therapy, expanded collaborations in research, and the adoption of precision medicine approaches.

The growth of the orphan drugs market is significantly propelled by the increasing prevalence of rare diseases. Rare diseases, affecting a small percentage of the population, necessitate treatments that often require a cold chain-a temperature-regulated supply chain not universally available in all countries. Globally, there has been a rise in the prevalence of rare diseases, exemplified by approximately 54,000 new cases of oropharyngeal or oral cancer reported annually in the USA as of January 2022. With 11,230 fatalities attributed to these cancers, the increasing incidence of rare diseases, even in young individuals, is a driving force for the orphan drugs market.

The growing utilization of orphan drugs in the realm of hematology is poised to propel the orphan drugs market forward. Hematology, a medical discipline focused on blood-related disorders, benefits from orphan drugs by offering therapeutic solutions for rare and orphan blood disorders. These drugs target specific genetic mutations and cellular processes, alleviating the need for blood transfusions, minimizing disease complications, and enhancing patients' quality of life. As of June 2021, more than 110,000 individuals are coping with blood disorders, and by 2035, the number in Australia is projected to surpass 275,000. Hence, the increasing application of orphan drugs in hematology is expected to be a key driver for market growth.

The absence of supportive government policies poses a hindrance to the orphan drugs market. The lack of specific policies for orphan drugs results in a dearth of special recognition or priority for regulatory approval. Companies manufacturing orphan drugs often face challenges in foreign markets due to insufficient government funding. In India, for instance, orphan medical products (OMPs) lack clear regulations and guidelines, depriving them of tax cuts or exemptions from customs duties. Consequently, the absence of favorable government policies acts as a constraint on the growth of the orphan drugs market.

The approval of biological orphan drugs for multiple indications emerges as a significant trend propelling the growth of the orphan drugs market. Biological drugs, utilized in the treatment of rare diseases such as cancer, exhibit fewer side effects and are prevalent in the developed world where these diseases have a high incidence rate. An illustration of this trend is observed in the engagement of biological orphan drug expert Frederick D. Sancilio, Ph.D., by Cardax, Inc., to spearhead the company's biological orphan drug development program. Companies are strategically acquiring biological orphan drugs to enhance their commercial product portfolio and increase revenue.

Major players in the orphan drugs market are strategically focusing on product approvals, including orphan drug designation (ODD), to drive revenue growth. ODD is a regulatory status granted by health agencies, such as the U.S. Food and Drug Administration (FDA), to drugs and biologics developed for the treatment, prevention, or diagnosis of rare diseases or conditions. For instance, in October 2021, Tezepelumab received orphan drug designation (ODD) from the US FDA for treating eosinophilic esophagitis (EoE). Developed through a collaboration between AstraZeneca and Amgen, Tezepelumab is a monoclonal antibody drug undergoing priority review in the US for asthma patients.

In July 2021, AstraZeneca PLC, a UK-based company specializing in orphan drugs, acquired Alexion Pharmaceuticals Inc. for an undisclosed amount. This strategic acquisition bolstered AstraZeneca's scientific presence in immunology, solidifying its position in the research and development of drugs for individuals with rare diseases. AstraZeneca's commitment to R&D investments in various therapeutic areas, including oncology, cardiology, renal, respiratory, and immunology, was further reinforced by expanding into the realm of rare illnesses where limited authorized therapy options are available. Alexion Pharmaceuticals Inc. is a US-based biopharmaceutical company renowned for manufacturing orphan drugs.

Major companies operating in the orphan drugs market report are Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Applied Molecular Genetics Inc., Novo Nordisk A/S, Merck & Co. KG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., CSL Limited, Biogen Inc., Celgene Corporation, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Grifols SA, Alexion Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Aegerion Pharmaceuticals Inc., Sankyo Co. Ltd., Shire PLC, Actelion Pharmaceuticals Ltd.

North America was the largest region in the global orphan drugs market in 2023. Middle East is expected to be the fastest growing region in the orphan drugs market report during the forecast period. The regions covered in the orphan drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the orphan drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The orphan drugs market consists of sales of ivacaftor and alglucerase. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Orphan Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on orphan drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for orphan drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The orphan drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Therapy Area: Oncology; Blood; Central Nervous System; Endocrine; Cardiovascular; Respiratory; Immunomodulatory
• 2) By Diseases Type: Oncology; Hematology; Neurology; Cardiovascular; Other Disease Types
• 3) By Drug Type: Biological; Non-Biological
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Sales
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F Hoffmann-La Roche Ltd.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Orphan Drugs Market Characteristics

3. Orphan Drugs Market Trends And Strategies

4. Orphan Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Orphan Drugs Market Size and Growth

• 5.1. Global Orphan Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Orphan Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Orphan Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Orphan Drugs Market Segmentation

• 6.1. Global Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oncology
• Blood
• Central Nervous System
• Endocrine
• Cardiovascular
• Respiratory
• Immunomodulatory
• 6.2. Global Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oncology
• Hematology
• Neurology
• Cardiovascular
• Other Disease Types
• 6.3. Global Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Biological
• Non-Biological
• 6.4. Global Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Sales

7. Orphan Drugs Market Regional And Country Analysis

• 7.1. Global Orphan Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Orphan Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Orphan Drugs Market

• 8.1. Asia-Pacific Orphan Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Orphan Drugs Market

• 9.1. China Orphan Drugs Market Overview
• 9.2. China Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Orphan Drugs Market

• 10.1. India Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Orphan Drugs Market

• 11.1. Japan Orphan Drugs Market Overview
• 11.2. Japan Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Orphan Drugs Market

• 12.1. Australia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Orphan Drugs Market

• 13.1. Indonesia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Orphan Drugs Market

• 14.1. South Korea Orphan Drugs Market Overview
• 14.2. South Korea Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Orphan Drugs Market

• 15.1. Western Europe Orphan Drugs Market Overview
• 15.2. Western Europe Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Orphan Drugs Market

• 16.1. UK Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Orphan Drugs Market

• 17.1. Germany Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Orphan Drugs Market

• 18.1. France Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Orphan Drugs Market

• 19.1. Italy Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Orphan Drugs Market

• 20.1. Spain Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Orphan Drugs Market

• 21.1. Eastern Europe Orphan Drugs Market Overview
• 21.2. Eastern Europe Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Orphan Drugs Market

• 22.1. Russia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Orphan Drugs Market

• 23.1. North America Orphan Drugs Market Overview
• 23.2. North America Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Orphan Drugs Market

• 24.1. USA Orphan Drugs Market Overview
• 24.2. USA Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Orphan Drugs Market

• 25.1. Canada Orphan Drugs Market Overview
• 25.2. Canada Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Orphan Drugs Market

• 26.1. South America Orphan Drugs Market Overview
• 26.2. South America Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Orphan Drugs Market

• 27.1. Brazil Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Orphan Drugs Market

• 28.1. Middle East Orphan Drugs Market Overview
• 28.2. Middle East Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Orphan Drugs Market

• 29.1. Africa Orphan Drugs Market Overview
• 29.2. Africa Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Orphan Drugs Market Competitive Landscape And Company Profiles

• 30.1. Orphan Drugs Market Competitive Landscape
• 30.2. Orphan Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson Services Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Farbenfabriken Bayer AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Orphan Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Co.
• 31.3. AstraZeneca plc
• 31.4. GlaxoSmithKline plc
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Gilead Sciences Inc.
• 31.8. Applied Molecular Genetics Inc.
• 31.9. Novo Nordisk A/S
• 31.10. Merck & Co. KG
• 31.11. AbbVie Inc.
• 31.12. Teva Pharmaceutical Industries Ltd.
• 31.13. Regeneron Pharmaceuticals Inc.
• 31.14. CSL Limited
• 31.15. Biogen Inc.

32. Global Orphan Drugs Market Competitive Benchmarking

33. Global Orphan Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Orphan Drugs Market

35. Orphan Drugs Market Future Outlook and Potential Analysis

• 35.1 Orphan Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Orphan Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Orphan Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer